| Name | Title | Contact Details |
|---|
Our roots belong with the Custom Cabinetmaker. We were cabinetmakers for years and identify with the values and qualities of the custom cabinetmaker. When it comes to developing relationships with our customers, our mission is Success for those we work with, as we build those relationships on our core values of Create Win-Wins, Do the Right Thing, and Make it Better. Were fanatical about assembling a great team, who continue to "make it better" with great products and innovative services for the Custom Cabinetmaker, and have been since 1989.
Since its establishment, more than a decade back, TAG Group has successfully developed its image as a team of thorough professionals in diversified, yet integrated, business segments. Nurturing and holding a team with strong technical and managerial expertise, endeavoring service quality and diversity as well as professional approach and competence; the Group strives to become a one-source solution provider to multi-sectoral companies and continuously seek expansion in new and challenging business markets. TAG Group Companies: Tariq Abdul Ghani Maqbool & Co., Chartered Accountants TAG Consulting, L.L.C. TAG Consulting (Pvt.) Ltd. ICON Consultants (Pvt.) Ltd. Kestrel & Buzzard (Pvt.) Ltd. TAG Technologies (Pvt.) Ltd. Evaluation Grid (Pvt.) Ltd. Sight Media Management (Pvt.) Ltd.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.